News

Theravance Biopharma Announces Ampreloxetine Presentations At The International MSA Congress
The clinical, cardiovascular and neuroendocrine profile of ampreloxetine showed target engagement of residual peripheral autonomic neurons and a sustained standing blood pressure effect, which is ...
MPR2d
Iron Chaperone Granted Fast Track Status for Multiple System Atrophy
ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.
BioArctic: Exidavnemab phase 2a study expanded to include MSA patients
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Exidavnemab phase 2a study expanded to include MSA patients
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System Atrophy (MSA) patients for treatment with ...
Twin study detects bacteria in small intestine that play role in development of multiple sclerosis
More than 280,000 people in Germany have multiple sclerosis (MS) and approximately 15,000 new cases are diagnosed each year.
TMCnet4d
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA - MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeuti ...
TMCnet6d
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity ...